首页> 外国专利> Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30

Inhibition of wet type age related macular degeneration (AMD) by adiponectin or acrp 30

机译:脂联素或acrp抑制湿性年龄相关性黄斑变性(AMD)30

摘要

The present invention provides new methods of treating wet type of age related macular degeneration by administering adiponectin (APN) or a functional fragment derived therefrom. One of the pathological complications of age related macular degeneration (AMD) is choroidal angiogenesis or choroidal neovascularization (CNV). The inventors discovered that the level of APN expression is significantly lower in the choroids of the laser-induced mouse model of choroidal angiogenesis or choroidal neovascularization (CNV) than that of the control mice and that administration of recombinant adiponectin (rAPN) or a peptide derived from the globular domain of the intact APN protein to the mouse model of CNV reduced the size of CNV significantly. These studies are the first to demonstrate the inhibitory effect of adiponectin on choroidal angiogenesis and thus provide the basis for treating a condition or disease involving angiogenesis, particularly age related macular degeneration, with administration of adiponectin.
机译:本发明提供了通过给予脂联素(APN)或由其衍生的功能性片段来治疗与年龄相关的湿性黄斑变性的新方法。年龄相关性黄斑变性(AMD)的病理并发症之一是脉络膜血管生成或脉络膜新血管形成(CNV)。发明人发现,在激光诱导的脉络膜血管生成或脉络膜新血管形成(CNV)小鼠模型的脉络膜中,APN表达水平明显低于对照小鼠,并且施用重组脂联素(rAPN)或肽衍生的肽的APN表达水平显着降低。从完整的APN蛋白的球状结构域到CNV小鼠模型,CNV的大小显着减小。这些研究是第一个证明脂联素对脉络膜血管生成的抑制作用的研究,因此为通过施用脂联素治疗涉及血管生成,特别是年龄相关性黄斑变性的疾病或病症提供了基础。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号